CAS 1265229-25-1

Debio-1347

Description:

Debio-1347, with the CAS number 1265229-25-1, is a small molecule that functions primarily as a selective inhibitor of the protein kinase known as fibroblast growth factor receptor (FGFR). This compound has garnered attention in the field of oncology due to its potential therapeutic applications in treating various cancers characterized by aberrant FGFR signaling. Debio-1347 exhibits a high degree of specificity for FGFR, which minimizes off-target effects and enhances its efficacy in cancer treatment. The substance is typically administered in a clinical setting, and its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are crucial for determining its dosing regimen and therapeutic window. Additionally, ongoing research is focused on understanding its mechanism of action, potential resistance mechanisms, and the overall impact on tumor microenvironments. As with many investigational drugs, safety and efficacy profiles are continuously evaluated through clinical trials to establish its role in cancer therapy.

Debio-1347

CAS: 1265229-25-1

Formula: C₂₀H₁₆N₆O

Purity: 99%

Color and Shape: Solid

Molecular weight: 356.3806

Ref: IN-DA009CM9

(5-Amino-1-(2-Methyl-1H-Benzo[D]Imidazol-6-Yl)-1H-Pyrazol-4-Yl)(1H-Indol-2-Yl)Methanone

CAS: 1265229-25-1

(5-Amino-1-(2-Methyl-1H-Benzo[D]Imidazol-6-Yl)-1H-Pyrazol-4-Yl)(1H-Indol-2-Yl)Methanone

Purity: 99%+

Molecular weight: 356.38g/mol

Ref: 54-OR1025696

Zoligratinib

CAS: 1265229-25-1

Zoligratinib

Purity: ≥95%

Molecular weight: 356.38g/mol

Ref: 54-BUP06137

Zoligratinib

CAS: 1265229-25-1

Zoligratinib (CH5183284) is a selective and orally available FGFR inhibitor, which is for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

Formula: C₂₀H₁₆N₆O

Purity: 95.28% - 99.51%

Color and Shape: Solid

Molecular weight: 356.38

Ref: TM-T6024

CH5183284

CAS: 1265229-25-1

CH5183284 is a monoclonal antibody that binds to the tyrosine kinase domain of the HER2 protein. It has been shown to inhibit angiogenesis in vitro, which may be due to its ability to block epidermal growth factor (EGF) signalling. This drug also inhibits EGF-induced migration of prostate cancer cells and skin cancer cells in vitro. CH5183284 has potential as a biomarker for tumours that overexpress HER2, as well as being a potential target for cancer therapy.

Formula: C₂₀H₁₆N₆O

Purity: Min. 95%

Molecular weight: 356.38 g/mol

Ref: 3D-QAC22925